Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CMPX | US
0.01
0.52%
Healthcare
Biotechnology
30/06/2024
04/10/2024
1.93
1.95
1.96
1.82
Compass Therapeutics Inc. a clinical-stage oncology-focused biopharmaceutical company engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009 a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1 and vascular endothelial growth factor A signaling pathways which are critical to angiogenesis and tumor vascularization; and CTX-471 an IgG4 monoclonal antibody that is an agonist of CD137 a key co-stimulatory receptor on immune cells. It also develops CTX-8371 a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics Inc. was founded in 2014 and is headquartered in Boston Massachusetts.
View LessPositive Momentum
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
60.7%1 month
70.6%3 months
90.0%6 months
82.0%-
-
1.77
-
-
-8.92
133.56
-
-54.50M
265.55M
265.55M
-
-1.77K
-
-
-30.05
6.05
2.37
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.41
Range1M
0.57
Range3M
1.23
Rel. volume
0.67
Price X volume
574.27K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Aviragen Therapeutics Inc | AVIR | Biotechnology | 3.46 | 292.10M | 2.67% | n/a | 0.43% |
THL Credit Inc. 6.75% Notes du | TCRX | Biotechnology | 5.51 | 291.89M | 5.15% | n/a | 35.68% |
Ocugen Inc | OCGN | Biotechnology | 1.01 | 290.74M | 4.12% | n/a | 40.56% |
Lexeo Therapeutics Inc. Common Stock | LXEO | Biotechnology | 8.66 | 286.31M | -0.69% | n/a | 6.58% |
Design Therapeutics Inc. Common Stock | DSGN | Biotechnology | 5 | 283.10M | 0.60% | n/a | 1.03% |
Rigel Pharmaceuticals Inc | RIGL | Biotechnology | 16.04 | 282.22M | -3.32% | n/a | -201.68% |
Abeona Therapeutics Inc | ABEO | Biotechnology | 6.46 | 279.81M | 3.69% | n/a | 31.63% |
Akebia Therapeutics Inc | AKBA | Biotechnology | 1.33 | 279.68M | -0.75% | n/a | -309.96% |
Nkarta Inc | NKTX | Biotechnology | 3.92 | 279.65M | -6.00% | n/a | 18.88% |
Editas Medicine Inc | EDIT | Biotechnology | 3.38 | 278.77M | 4.97% | n/a | 16.68% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.89 | 19.79M | -2.50% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.0599 | 19.14M | -0.93% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.695 | 8.47M | -4.15% | n/a | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.6199 | 5.90M | 6.82% | n/a | 19.98% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -8.92 | 0.76 | Cheaper |
Ent. to Revenue | 133.56 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 1.77 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 89.96 | 74.67 | Riskier |
Debt to Equity | - | -1.82 | - |
Debt to Assets | - | 0.26 | - |
Market Cap | 265.55M | 3.73B | Emerging |